Piper Sandler Companies (NYSE:PIPR) Q1 2024 Earnings Conference Call April 26, 2024 9:00 AM ET
Company Participants
Chad Abraham – Chairman and CEO
Deb Schoneman – President
Kate Clune – CFO
Conference Call Participants
Devin Ryan – JMP Securities
Brendan O’Brien – Wolfe Research
James Yaro – Goldman Sachs
Michael Grondahl – Northland Securities
Operator
Good morning, and welcome to the Piper Sandler Companies Conference Call to Discuss the Financial Results for the First Quarter of 2024. During the question-and-answer session, securities industry professionals may ask questions of management.
The company will make forward-looking statements on this call that are not historical or current facts, including statements about beliefs and expectations, and involve inherent risks and uncertainties. Factors that could cause actual results to differ materially from those anticipated are identified in the Company’s earnings release and reports on file with the SEC, which are available on the Company’s website at www.pipersandler.com and on the SEC website at www.sec.gov.
This call will also include statements regarding certain non-GAAP financial measures. The non-GAAP measures should be considered in addition to and not a substitute for measures of financial performance prepared in accordance with GAAP. Please refer to the Company’s earnings release issued today for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure. The earnings release is available on the Investor Relations page of the Company’s website and at the SEC website. As a reminder, this call is being recorded.
And now, I’d like to turn the call over to Mr. Chad Abraham. Mr. Abraham, you may begin your call.
Chad Abraham
Good morning, everyone. Thanks for joining us. It’s great to be with you to talk about our first quarter 2024 results. I am here with Deb Schoneman, our President; and Kate Clune, our CFO. During the first quarter, we generated adjusted net revenues of $334 million, a 16.8% operating margin and adjusted EPS of $2.79. While market headwinds persist, we’re encouraged by the improvement in certain businesses, most notably equity capital markets. Our diversified platform continues to perform well through varied cycles.
Corporate investment banking generated revenues of $210 million during the first quarter, a 25% increase over the same period last year, driven by higher revenues from both advisory and corporate financing. We benefited from the sector and product diversification of our business along with increased revenues from private equity clients.
Advisory services revenues were $157 million during the quarter and increased year-over-year driven by higher average fees. The trend of advising on larger transactions and generating larger fees continues to be a key driver of our results. We completed 57 advisory transactions during the first quarter. Performance was led by the best quarter on record from our energy and power team with solid contributions from our financial services, consumer and healthcare groups.
In addition, following a record 2023, both our restructuring and debt advisory groups started this year with strong results. The outlook for M&A has improved as CEO confidence strengthens. We expect our second quarter advisory revenues to be consistent with the first quarter before improving in the second half of 2024, resulting in revenue seasonality similar to last year.
Turning to corporate financing. The market for equity underwriting improved considerably during the quarter, driven by a more accommodative backdrop and increased demand from companies looking to raise capital. For context, the economic fee pool was approximately $2 billion during the quarter, almost double the average of the last eight quarters and more in line with normalized levels. The sub $5 billion market cap fee pool also increased meaningfully and included an outsized contribution from healthcare.
Corporate financing revenues were $53 million during the first quarter, nearly double the prior year quarter, driven by higher average fees and more completed transactions. We completed 35 equity, debt and preferred financings, raising over $10 billion for corporate clients. Performance was led by our market leading healthcare franchise, which served as book runner on 19 of the 20 equity deals priced during the quarter. Looking ahead, if this level of market activity is sustained, we expect participation will broaden across sectors.
Turning to investment banking managing director headcount. Our approach has not changed and we continue to target the addition of five to seven MDs annually. We added a net two managing directors during the quarter, finishing with 171 MDs. We remain focused on strengthening sector coverage and expanding our product offerings and we are well positioned to drive revenue growth as markets continue to normalize.
During the last several years, we have grown our market leadership meaningfully and Piper Sandler is increasingly seen as a destination of choice for talented professionals and teams looking to leverage our full suite of products to better serve their clients and grow their book of business. Our recruiting pipeline is robust with a number of investment banking managing directors slated to start during the second and third quarters of this year.
Over the long-term, we remain focused on growing our corporate investment banking revenues by continuing to advance corporate development, scaling industry teams, gaining market share with a focus in technology, increasing our product delivery to private equity clients and continuing to build out our equity capital markets business with a disciplined focus in each of our industry sectors.
With that, I will turn the call over to Deb to discuss our public finance and brokerage businesses.
Deb Schoneman
Thanks, Chad. I’ll begin with an update on our public finance business. While interest rates trended higher during the quarter, the market for higher yielding municipal debt offerings has thawed. Credit spreads have tightened due to increased investor demand, allowing us to execute on a number of specialty transactions. We generated $21 million of municipal financing revenues during the first quarter of 2024, up 23% year-over-year driven by our specialty sector business.
We underwrote 86 municipal negotiated transactions raising $4 billion of par value for our clients. Performance during the quarter was driven by our real estate, healthcare and affordable housing sectors as well as our state and local government practice in Texas and Washington. As we look ahead, we believe a period of sustained municipal fund inflows and lower nominal interest rates are needed for middle market issuance to increase.
Turning to our equity brokerage business. Equity markets saw muted volatility during the first quarter as markets ground higher with indices hitting new highs. We generated revenues of $49 million for the first quarter of 2024, down 8% from the first quarter of last year, which benefited from increased volatility. We traded 2.6 billion shares during the quarter on behalf of over 1,200 unique clients as they sought our market leading research, corporate access and trading capabilities.
We continue to see client research votes increasing as we demonstrate the value of our capabilities and ability to assist clients generate alpha. During the quarter, we hired a senior research analyst in healthcare with coverage focused on biotech companies, a key addition in the build out of our biotech franchise. With muted volatility, we see near-term results to be relatively consistent with the first quarter, while expecting increased volumes and activity in the second half of the year.
Lastly, turning to fixed income. We generated revenues of $42 million for the first quarter of 2024, consistent with the year ago quarter. Client activity is slowly improving but remains fairly muted as market participants wait for more certainty on interest rates. The breadth of our client relationships and product capabilities continues to provide a level of resiliency to our results. Public entity clients were active as they found relative value in the short end of the yield curve, while insurance companies were active due to the higher rate environment.
Now I will turn the call over to Kate to review our financial results and provide an update on capital use.
Kate Clune
Thanks, Deb. As a reminder, my comments will address our adjusted non-GAAP financial results, which should be considered in addition to and not a substitute for the corresponding GAAP financial measures. Net revenues of $334 million for the first quarter of 2024 increased 15% compared to the year ago quarter, driven by higher corporate investment banking revenues, primarily equity capital markets.
Turning to operating expenses and margin. Our compensation ratio was 63.1% for the first quarter of 2024, lower compared to the prior year quarter driven by increased net revenues. Our compensation philosophy remains unchanged. We will continue to exercise solid operating discipline, balancing employee retention, investment opportunities and near-term margin.
Based on our current outlook of improving conditions and recruiting opportunities, we continue to expect our compensation ratio for the full year of 2024 to be near this level. Non-compensation expenses for the first quarter of 2024, excluding reimbursed deal expenses were $61 million. We continue to focus on managing the actionable non-compensation expenses as they are a key driver of operating leverage.
During the first quarter of 2024, we generated operating income of $56 million and an operating margin of 16.8%, highlighting the earnings capacity of our platform. Our income tax rate was 10.7% for the first quarter of 2024. Income tax expense for the first quarter was reduced by $11 million of tax benefit related to restricted stock award vestings. Excluding these benefits, our first quarter tax rate was 29.6%. We continue to expect our full year tax rate to be within a range of 27% to 29%, excluding the impact from stock vestings.
During the first quarter of 2024, we generated net income of $50 million and a diluted EPS of $2.79. Let me finish with an update on capital allocation. Our earnings resilience and capacity, combined with our capital light approach, enables us to generate meaningful amounts of excess cash to deploy through share repurchases, dividends and corporate development. We remain committed to returning capital to shareholders through market cycles.
During the first quarter of 2024, we returned an aggregate of $88 million to shareholders through buybacks and dividends paid. We repurchased approximately 289,000 shares of our common stock or $52 million related to employee tax withholding on the vesting of restricted stock awards. These repurchases more than offset the share count dilution from this year’s annual stock grants.
We also paid an aggregate of $36 million or $1.60 per share to our shareholders through our quarterly and special cash dividends. In addition, the Board approved a quarterly cash dividend of $0.60 per share to be paid on June 7th to shareholders of record as of the close of business on May 24.
Our first quarter results demonstrate the firm’s resiliency during the mixed market conditions and our profitability metrics reflect strong performance relative to our peer set. We remain focused on providing near-term value to our shareholders, while continuing to grow our platform and we’re strongly positioned to accelerate earnings growth as markets continue to normalize.
With that, we can open up the call for questions.
Question-and-Answer Session
Operator
[Operator Instructions] And we’ll take our first question from Devin Ryan with Citizens JMP. Please go ahead.
Devin Ryan
Great. Good morning, everyone. How are you?
Chad Abraham
Good. Hey, Devin.
Devin Ryan
Hey. First question, just want to hit on kind of the advisory outlook. And Chad, I heard you comment that private equity clients were more active or drove a bigger contribution in the quarter. And just love to get a little more color around that client base. And how, I guess, recent moves in interest rates are affecting kind of the recovery you’re seeing there and whether the recovery is coming back at a fast pace or if you think this is going to play out over a couple of years? Just trying to think about what the current conditions look like and then how you think about kind of a normalization for sponsors, which have really been out of the market for the past couple of years.
Chad Abraham
Yeah. I think, Devin, we all got to keep in mind that compared to the first couple quarters of 2023, that was sort of a trough level. And so our PE contribution to M&A was definitely better than first quarter of last year, but again, off of a pretty low comp. So we’ve definitely seen an improvement for the most part, at least on the middle market deals. If a sponsor wants to do the deal, they can get financing, but it’s still not by any means a great environment. So I think this build is just a pretty slow build.
And then, as we’ve talked about many times, if we look back many years, our sponsor business just tends to be a little more seasonal in the back half versus the front half. And a lot of that just has to do with a lot of processes kind of starting in the spring, hoping to close in the fall, trying to get full credit for that year’s financials.
Devin Ryan
Okay. Got it. Really, helpful. Thanks, Chad. And then a follow up here just on the recruiting landscape. You mentioned that a couple of times on the call and 2023 was a little bit of a slower year of recruiting, but you had very active years, maybe more so than some of the peers in the couple of years leading into 2023. So is there any way to kind of frame out what you’re hoping to accomplish on recruiting in 2024? And then beyond recruiting, how you’re thinking about maybe inorganic lift out or opportunities to do small M&A? Thanks.
Chad Abraham
Yeah. I would say, on the investment banking side of recruiting, we actually did about the same amount of hiring in 2023. I would say when you hit these tough periods, like 2022 and 2023, we’re a little more careful. There’s some — there’s some MDs that if they’re not productive, work off the platform. So there’s a little bit of a netting going on there for us, probably in 2023 more than other years, just given the environment. But we do feel pretty good about the recruiting pipeline. We called out that both in Q2 and Q3, we should have some good announcements. We have a good slate of the five to seven kind of MDs that we usually talk about adding. We have that number sort of lined up, ready to go.
And then, I would say our outlook. Yeah, I think if you look back, 10 years, we’ve — unless we do a big M&A deal, we’ve just kind of been averaging that number, and I think, we’ll just keep that steady pace. I would say we’re — given relative performance, we’re probably seeing more opportunities than we usually do. But we’re also being, very careful with the environment to kind of add the right people and really try to add MDs that boost productivity and boost the average and boost the franchise and quality.
Devin Ryan
Okay, terrific. Maybe squeeze one more in just on kind of the comp ratio interplay. So, heard the commentary from Kate around kind of around the 63% level. As we think about a recovery scenario for capital markets, like how should we think about — I know you guys have given ranges before, but just think about kind of the comp leverage that will be inherent in the model? And maybe what a more normalized compensation ratio for you guys looks like now as the firm evolves?
Chad Abraham
Yeah. I mean, I’ve sort of given this answer before. I mean, obviously, we’ve had — not a lot, but years where we’ve gotten it closer to 60% or 61%. We always think about 61.5% or 62% probably is closer to in a good environment, normalized. I do think we’re being careful this year, given some of the hiring opportunities. And even though Q1 2024 was up over Q1 2023, I mean, it was all marginal. So I think we’re still being careful about that comp ratio, which is why we made the comment that we expect it for this year to stay in and around that level. Obviously, if we get some revenue upside, we’ll do better than that.
Devin Ryan
Yeah. Okay, terrific. I’ll get back in the queue. Thanks, guys.
Operator
Thanks. And we’ll take our next question from Steven Chubak with Wolfe Research. Please go ahead.
Brendan O’Brien
Good morning. This is Brendan O’Brien filling in for Steven. To start, I just want to get an update on the opportunity with your bank clients, given it’s now been a little over a year since the SBB and SBNY collapses. I just want to get a sense as to what you’re hearing from your bank clients across your different business lines. And how has the potential rollback of Basel III endgame impacted your expectation for the sizing or timing of this opportunity?
Chad Abraham
Yes. What I would say about our depository business, obviously, we got pretty diversified across sectors, honestly, Q1 was probably on the lower side for our financial services group and our depository group. And I would actually argue the last couple quarters, the environment for M&A and depositories, it may have even gotten tougher just with the different regulatory agencies looking at things and just looking at the financial results, how the stocks are performing.
So we — I think like we’ve been saying for the last couple quarters, we expect depository environment to stay difficult. There’s still opportunities within that when there’s some capital raising, some ability to do some recapitalization on the equity side, some debt financing and we’re still have a steady stream of smaller deals, but anything of size continues to be very difficult.
Brendan O’Brien
Got it. And I guess for my follow-up, I want to move over to ECM and underwriting. While the biotech ECM market has been dormant for much of the past two years, as you know in your prepared remarks, there’s been a notable pickup in activity year to date. However, I just want to get a sense as to whether this result is sustainable, in your view, or did 1Q benefit from what is likely significant pent-up demand for capital in this space?
Chad Abraham
Yes. I would honestly say it’s probably somewhere in between there. We made some — I made some comments just about the total overall fee pool across the Street. It was a good quarter for ECM. We definitely had a good quarter. We had some outsized biotech performance. I would say we have a really good backlog there, as I think obviously people can see our deal logic numbers. If I think about April, we’re probably still on that same kind of run rate for ECM.
But this isn’t a business where we have visibility six months out. It depends on what happens with the equity markets and the mood of investors that particular week. But I think based on what we’re seeing now and the deals we’re doing, we feel pretty good. We feel pretty good about that environment. And I would say, we’ve just started to see across some of the other industry teams, a little more activity in IPOs, a little more activity in energy. We were on an IPO in financials, so a little bit of discussion around broadening to some of the industries, but that’s going to be very tied to the overall market. So I mean, if we get some big negative correction, that’s never good for the mood of new issues.
Brendan O’Brien
That’s great color. Thank you for taking my questions.
Operator
And we’ll take the next question from James Yaro with Goldman Sachs. Please go ahead.
James Yaro
Hey. Good morning, and thanks for taking my questions. Chad, these were excellent advisory results and I think especially strong versus the publicly available data. Maybe you could just help us understand some of the moving parts here. I know you talked about higher fees, but maybe just on the other businesses within advisory, aside from M&A, such as restructuring and then I guess other advisory and perhaps the outlook for these. And then secondly, do you feel more or less comfortable about the cadence of the advisory build versus the beginning of the year when we had five or six rate cuts in expectations?
Chad Abraham
Yeah. So maybe just a few comments on Q1 advisory. We had a — one business we’re incredibly proud of right now is our energy business, that obviously we did the Simmons deal in 2015 and we’ve had various cycles, but I would say relative to peers, some people that really cut back in energy, we stayed pretty committed and we’ve really broadened that out.
Obviously, we got a lot of history in oilfield services, but we’re doing a lot in E&P and development. We’re doing a lot in our midstream and that business and frankly, now in energy transition. So we got a great, great pipeline in energy, but also had pretty balanced, I think, healthcare and financials and industrials, they were all about the same size. So we’re just benefiting from that diversification.
As far as the cadence, like I said, while the results were good on a peer basis and versus last year, still relatively depressed levels. And that’s not getting a lot better anytime quick. It’s getting better and it’s improving, but it’s a pretty slow pace. Can I see a noticeable difference in the last few weeks with sort of the different inflection points on rates? Probably not, but it obviously can’t be great for the business.
So I think our conclusion and based on our pipeline is private equity has definitely picked their head up. They’re definitely — we’re definitely seeing more pitches. We’re definitely starting more processes and we’ll definitely continue to see an improvement. But I think like we’ve been saying, it’ll be a slow improvement.
James Yaro
Okay. That makes a lot of sense. Maybe just on non-comps, you did demonstrate strong non-comps discipline again this quarter. Maybe just an update on the outlook for non-comp costs for the rest of the year.
Kate Clune
Good morning, James. This is Kate. So for non-comps, we kind of reiterate our guidance of that $62 million per quarter, excluding those reimbursed deal expenses. We remain really committed to a lot of discipline in that space and want to ensure we’re controlling the expenses that we’re able to control. That being said, we’ve seen a little bit of a pickup in terms of T&E expense, as expected, and there’s going to be continued pressure as it pertains to things like datacom services and occupancy. So again, maintaining that discipline around the areas we can control, consistent guidance with that $62 million a quarter, excluding those deal expenses, and really focused on maintaining that debt level.
James Yaro
Okay. Really appreciate it. Thank you.
Operator
[Operator Instructions] We’ll take our next question from Michael Grondahl with Northland Securities. Please go ahead.
Michael Grondahl
Hey, thank you. Hey, Chad. When you talked about, recruiting and kind of having five to seven banking MDs ready to go for 2Q and 3Q, could five to seven end up proving low? Is that something kind of coming out of your messaging there, that this could be sort of a higher level than that by the time we get to 2024?
Chad Abraham
Yeah. I mean, the reason we sort of said the five to seven is typically it’s sort of 90 to 100 days to onboard. There’s garden leave. There’s the various sectors. That’s sort of the group we have lined up today. Now we happen to be in sort of the heavy recruiting season. Could it be a couple higher than that? Maybe, but the chances of adding people the later we get into the year is less. But I would say compared to a normal year, particularly on the banking side, yeah, we’ve done a little bit more than we normally would by this time in May. So we feel pretty good about — we feel pretty good about where we’re going to be with those adds towards the end of the year.
Michael Grondahl
Got it. And then on the corporate finance comments, it sounded like you were saying that you had a very robust $53 million in 1Q and that April was pretty solid or kind of maintained that level. But the outlook, the visibility isn’t that far out, but at least into April, it kind of maintain that level. Did I hear that right?
Chad Abraham
Yeah. I mean, nothing’s really changed. We’ve got a great pace. We’ve done a bunch of good deals in April that I, is on the same run rate as March. If things don’t change, you would feel great about that for the quarter. But this is also a business that you just don’t get five months of visibility. And even if you do and you have deals lined up, things change quick.
So we definitely feel better about the ECM business and frankly, our debt financing business. And so pending not a lot of change in the overall market, it’ll be a nice up year in ECM. It’s just I don’t like to make comments on ECM two and three quarters out because things can change pretty fast.
Michael Grondahl
Sure. Okay. Hey, thanks a lot.
Operator
It appears there are no further questions at this time. I will now turn the conference back to Mr. Chad Abraham for any additional or closing remarks.
Chad Abraham
All right. Thank you, operator, and everyone that joined. We look forward to updating you on our second quarter results. Have a great day and a good weekend.
Operator
This concludes today’s call. Thank you for your participation. You may now disconnect.
